Bring NGS testing in-house with clinical decision support software for oncology and hereditary diseases
For molecular diagnostic labs performing variant interpretation and reporting in-house, QIAGEN Clinical Insight (QCI) Interpret is clinical decision support software that enables faster turnaround times, higher confidence reporting, and test menu expansion for oncology and inherited diseases.
QCI Interpret applications:
The phrase, “knowledge is power,” couldn’t be truer when it comes to diagnosing hereditary diseases.
With QCI Interpret, you can be confident that every clinical recommendation you make is backed by the latest peer-reviewed publications, clinical practice guidelines, FDA therapeutics, and open clinical trials, all vetted by M.D. and Ph.D.-level expert curators who do the reading for you.
Unlike other clinical decision support tools and search engines, QCI Interpret delivers manually curated evidence directly to your pipeline. You receive links to all articles, auto-computed ACMG/AMP or AMP/ASCO/CAP classifications, and access to over 1 million unpublished variant-phenotype relationships from the QIAGEN Knowledge Base.
Weekly data import
A team of over 200 PhD and MD ISO:9001 certified curators updates QCI Interpret’s knowledge base weekly with molecular and therapeutic data from over 40 public and proprietary databases, including clinical trial registries and drug label information.
Application of artificial intelligence (AI)
QCI Interpret scans its expert-curated knowledge base content, which has been amassing for over 20 years, to show the most clinically relevant results first. Lab personnel can then decide whether or not to include certain evidence in the final report.
Automated variant classifications
QCI Interpret automatically incorporates diagnostic and prognostic criteria supporting tier classifications of the ACMG/AMP and AMP/ASCO/CAP professional guidelines, as well as cytogenetic results, the variant’s reported frequency, and geographically matched trials.
With QCI Interpret’s clinical decision support capabilities, a patient’s NGS test results can be rapidly interpreted and reported with confidence and accuracy to deliver clear, evidence-based reports in a fraction of the time.
QCI Interpret helps you provide your ordering physicians and oncologists with the best information needed to make timely, informed decisions about their patients’ treatment and care.
Small to mid-size genetic testing labs are challenged with growing test volumes, labor-intensive interpretation processes, and minimal test reimbursement. For labs performing high-throughput genetic tests, such as expanded carrier screening (ECS), the question becomes how to scale-up operations without cutting corners.
Download this whitepaper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QCI Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%.
Hear from Dr. Anthony M Magliocco, CEO and Founder of Protean BioDiagnostics, as he discusses the application of whole exome sequencing (WES) for guiding clinical trial enrollment for patients with cancer.
However, implementing WES in clinical practice remains challenging due to difficulties in variant interpretation, large dataset management, and workflow integration. That why Protean BioDiagnostics partnered with QIAGEN Digital Insights to create an adaptable and innovative framework using QCI Interpret.
Request a free personalized demonstration
Request a free personalized demonstration
Empower clinicians and their patients to make critical and timely healthcare decisions with the latest publications and clinical evidence
Provide ordering oncologists with the best information needed to make timely, educated decisions about their patients’ cancer treatment plans
Leverage the benefits of automation and expert support to improve test turnaround times and clinical reporting capabilities
Product Disclaimer: QCI Interpret is an evidence-based decision support software intended as an aid in the interpretation of variants observed in genomic next-generation sequencing data. The software evaluates genomic variants in the context of published biomedical literature, professional association guidelines, publicly available databases, annotations, drug labels, and clinical-trials. Based on this evaluation, the software proposes a classification and bibliographic references to aid in the interpretation of observed variants. The software is NOT intended as a primary diagnostic tool by physicians or to be used as a substitute for professional healthcare advice. Each laboratory is responsible for ensuring compliance with applicable international, national, and local clinical laboratory regulations and other specific accredidations requirements.